Press release
Leber Congenital Amaurosis Market to Reach USD 1.4 Billion by 2034
Leber Congenital Amaurosis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72261
The approval of gene therapies such as Luxturna (voretigene neparvovec-rzyl) has transformed the treatment landscape, creating momentum for genetic testing, early diagnosis, and precision medicine. Increasing investments in orphan drug development, retinal cell therapy, and CRISPR-based gene editing are fueling global market expansion.
Market Overview
• Market Size (2024): USD 612 million
• Forecast (2034): USD 1.4 billion
• CAGR (2025-2034): 8.4%
Key Highlights:
• Luxturna remains the only FDA- and EMA-approved gene therapy for RPE65-mutation LCA.
• Growing number of clinical trials in gene therapy and RNA-based therapeutics.
• Increased use of genetic testing and newborn screening for early detection.
• Rising patient advocacy and orphan drug incentives boosting R&D.
Segmentation Analysis
By Therapy Type:
• Gene Therapy (Luxturna, pipeline AAV therapies - fastest growing)
• RNA-Based Therapies (antisense oligonucleotides, emerging)
• Stem Cell Therapy (preclinical & early clinical)
• Supportive Therapies (vitamin A supplements, low vision aids)
• Others (experimental treatments, combination regimens)
By Route of Administration:
• Subretinal Injection (dominant for gene therapy)
• Intravitreal Injection (explored for antisense and gene therapies)
• Oral/Adjunctive
By Patient Type:
• Pediatric (largest share due to early onset)
• Adult
By Distribution Channel:
• Hospital & Specialty Clinics
• Academic & Research Institutes
• Online/Pharmacy Networks (supportive care products)
Segmentation Summary:
Gene therapy dominates today's market, with pipeline expansion into antisense and CRISPR-based approaches expected to broaden treatment options.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72261/leber-congenital-amaurosis-market
Regional Analysis
North America
• Largest market (~45% share in 2024).
• High adoption of Luxturna and advanced genetic testing.
• Strong presence of leading biotech innovators and funding for rare disease R&D.
Europe
• ~32% share.
• Germany, UK, and France lead in orphan ophthalmic disease research.
• EMA approvals and reimbursement pathways strengthening therapy uptake.
Asia-Pacific
• Fastest-growing region, CAGR ~9.6%.
• Large patient pool due to higher birth rates and consanguinity-related genetic disorders.
• Expanding clinical trial activity in China, Japan, and India.
Latin America
• Brazil and Mexico gradually expanding rare disease therapy access.
• Limited but rising availability of genetic testing.
Middle East & Africa
• GCC nations expanding access to genetic screening.
• Significant unmet need due to limited infrastructure in most African regions.
Regional Summary:
North America and Europe lead today's market, but Asia-Pacific will outpace others in growth due to rising patient identification and trial participation.
Market Dynamics
Key Growth Drivers:
• Success of gene therapy (Luxturna) paving the way for broader applications.
• Increasing adoption of genetic testing and newborn screening.
• Strong patient advocacy and orphan drug funding initiatives.
• Advances in gene editing, RNA therapies, and cell therapy.
Key Challenges:
• Extremely high therapy costs (Luxturna priced above USD 800,000).
• Limited patient eligibility based on genetic subtype.
• Small patient pool complicating large-scale clinical trials.
• Reimbursement and access disparities across regions.
Latest Trends:
• Expanding CRISPR-based editing trials for CEP290-related LCA.
• Development of antisense oligonucleotide therapies targeting splicing mutations.
• Partnerships between academic labs and biotech companies to accelerate pipeline.
• Growth of AI-driven retinal imaging for early diagnosis.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72261
Competitor Analysis
Major Players in the Market:
• Spark Therapeutics (Roche) - Luxturna (RPE65 gene therapy)
• Editas Medicine, Inc. - CRISPR-based therapies for CEP290 mutations
• ProQR Therapeutics - RNA therapies (sepofarsen, others)
• MeiraGTx Holdings plc - AAV-based gene therapies
• Regenxbio Inc.
• Applied Genetic Technologies Corporation (AGTC)
• Nanoscope Therapeutics Inc. (optogenetics)
• Biogen Inc.
• Novartis AG
• IVERIC bio (Astellas Pharma)
Competitive Summary:
Spark Therapeutics leads with Luxturna, while Editas and ProQR are pioneering RNA and CRISPR therapies. Regenxbio and MeiraGTx expand the AAV pipeline, while Nanoscope explores optogenetics. Partnerships and orphan drug approvals are central to competitive strategies.
Conclusion
The Leber Congenital Amaurosis Market, valued at USD 612 million in 2024, is projected to reach USD 1.4 billion by 2034, expanding at a CAGR of 8.4%.
Key Takeaways:
• Gene therapy dominates, with Luxturna setting the benchmark.
• CRISPR and antisense therapies are the next frontier.
• North America and Europe lead adoption, while Asia-Pacific grows fastest.
• Patient advocacy and orphan drug incentives are vital to market expansion.
The next decade will witness a paradigm shift from supportive care to curative therapies, with gene editing and precision medicine driving breakthroughs for patients with Leber congenital amaurosis.
This report is also available in the following languages : Japanese (レーバー先天性黒内障市場), Korean (레버 선천성 흑암시 시장), Chinese (莱伯先天性黑蒙症市场), French (Marché de l'amaurose congénitale de Leber), German (Markt für Leber-kongenitale Amaurose), and Italian (Mercato dell'amaurosi congenita di Leber), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72261/leber-congenital-amaurosis-market#request-a-sample
Our More Reports:
Skin Structure Infections Market
https://exactitudeconsultancy.com/reports/72883/skin-structure-infections-market
Hypertrophic Cardiomyopathy Market
https://exactitudeconsultancy.com/reports/72884/hypertrophic-cardiomyopathy-market
Helicobacter Pylori Market
https://exactitudeconsultancy.com/reports/72885/helicobacter-pylori-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leber Congenital Amaurosis Market to Reach USD 1.4 Billion by 2034 here
News-ID: 4194289 • Views: …
More Releases from Exactitude Consultancy
Centronuclear Myopathy Market Projected to Grow at 7.8% CAGR
Introduction
Centronuclear myopathy (CNM) is a rare genetic neuromuscular disorder characterized by abnormal central positioning of nuclei in skeletal muscle fibers, leading to muscle weakness, hypotonia, delayed motor milestones, and in severe cases, respiratory complications. It includes subtypes such as X-linked myotubular myopathy (XLMTM), autosomal recessive CNM, and autosomal dominant CNM.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72249
Although treatment is largely supportive today, breakthroughs in gene therapies, enzyme replacement…
Choroidal Neovascularization Market to Reach USD 18.9 Billion by 2034
Choroidal neovascularization (CNV) refers to the growth of abnormal blood vessels from the choroid into the subretinal space, commonly associated with age-related macular degeneration (AMD), high myopia, ocular trauma, and inflammatory diseases. CNV is a leading cause of vision loss in working-age and elderly populations, making it a critical focus in ophthalmology.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72251
The introduction of anti-VEGF therapies, laser photocoagulation, photodynamic therapy (PDT),…
Corneal Epithelial Defect Market to Reach USD 2.5 Billion by 2034
Corneal epithelial defects (CEDs) are disruptions in the corneal epithelium, often caused by trauma, infections, contact lens misuse, refractive surgery, or underlying systemic conditions like diabetes and autoimmune disorders. Left untreated, CEDs can lead to infections, scarring, recurrent erosions, and vision loss, making early diagnosis and treatment crucial.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72253
With the increasing global burden of ocular surface diseases, rising cataract/refractive surgeries, and corneal…
Cataract Surgery Complications Market Projected to Grow at 7.5% CAGR
Introduction
Cataract surgery is the most common ophthalmic surgical procedure worldwide, with millions of procedures performed annually. While advances in surgical techniques and intraocular lens (IOL) technologies have improved outcomes, post-operative complications such as posterior capsule opacification (PCO), cystoid macular edema (CME), endophthalmitis, retinal detachment, and corneal edema remain significant clinical and economic concerns.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72247
The growing global population, increasing number of elderly patients,…
More Releases for Leber
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Europe Leber Congenital Amaurosis Market 2023 - Growth, Trends, Market Size
The Europe Leber Congenital Amaurosis Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Europe Leber Congenital Amaurosis market. This report explores all the key factors affecting the growth of the global…
MEA Leber Congenital Amaurosis Market Size, Share, Industry, Forecast to 2029
The MEA Leber Congenital Amaurosis Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global MEA Leber Congenital Amaurosis market. This report explores all the key factors affecting the growth of the global…
Leber Congenital Amaurosis Market To Reach USD 89.84 Million by 2029
To elaborate the studies and estimations involved in the supreme Leber Congenital Amaurosis market report, a method of standard market research analysis which is SWOT analysis is put forth. This market report opens the door to acquire knowledge about the Healthcare industry which explains what market definition, classifications, applications, engagements and market trends are. The report makes it effortless to identify the types of consumers, their response and views about…
Leber Congenital Amaurosis Market by Players and Application 2024
Leber Congenital Amaurosis Market: Overview
Leber congenital amaurosis (LCA) is a disorder of eye mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for detection of light and color. People, primarily babies suffering with this disorder have severe visual impairment from the first year of life. The visual impairment because of this disorder likely to be stable for the rest of the life, whereas…
Leber Congenital Amaurosis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Leber Congenital Amaurosis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis - Pipeline Review, H1 2017, provides an overview of the Leber Congenital Amaurosis (Genetic Disorders) pipeline landscape.
Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the…
